← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Altis Biosystems, Inc.
Durham, NC
$11,282,656
Total funding
13
Grants
Funding over time
peak $3.1M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,282,656 · 13
By mechanism
R44$9,438,384 · 6
R43$1,844,272 · 7
Investigators at Altis Biosystems, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$992,302
R44 · FY2022 · TR
A 2D Intestinal Crypt Platform for Compound Screens$988,431
R44 · FY2022 · DK
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$988,414
R44 · FY2023 · TR
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$913,659
R44 · FY2023 · TR
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$913,659
R44 · FY2024 · TR
A 2D Intestinal Crypt Platform for Compound Screens$900,267
R44 · FY2023 · DK
Mucus and ALI Models of the Human Intestine$835,939
R44 · FY2025 · DK
Co-culture cassette for anaerobes and primary human intestinal epithelium$747,640
R44 · FY2019 · DK
Co-culture cassette for anaerobes and primary human intestinal epithelium$745,742
R44 · FY2020 · DK
Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system$712,990
R44 · FY2020 · DK
Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system$699,341
R44 · FY2021 · DK
MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes.$343,297
R43 · FY2023 · TR
A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing$293,991
R43 · FY2022 · DK
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$256,574
R43 · FY2022 · TR
A 2D Intestinal Crypt Platform for Compound Screens$256,543
R43 · FY2021 · DK
Generating drug-screenable primary human intestinal epithelium by gene-editing and transgenesis$245,920
R43 · FY2020 · DK
Co-culture cassette for anaerobes and primary human intestinal epithelium$224,898
R43 · FY2018 · DK
Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening$223,049
R43 · FY2019 · DK